Skip to main content
. 2018 Sep 25;10:1758835918797589. doi: 10.1177/1758835918797589

Figure 2.

Figure 2.

Progression-free survival (a) and overall survival (b) in patients with non-small cell lung cancer and epidermal growth factor receptor gene mutations treated with gefitinib, erlotinib, or afatinib.

CI, confidence interval; NR, not reached.